

## Drug Monograph

Drug Name: **Abilify Mycite<sup>®</sup> (aripiprazole) oral tablet with sensor**  
**CNS: Antipsychotics, Atypical (2<sup>nd</sup> Generation) Oral and**  
 Drug Class: **Transdermal Products**  
 Prepared For: MO HealthNet  
 Prepared By: Conduent

**New Criteria**

**Revision of Existing Criteria**

### Executive Summary

**Purpose:** The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

**Dosage Forms:** Abilify Mycite is a drug-device combination product comprised of aripiprazole tablets embedded with an Ingestible Event Marker (IEM) sensor intended to track compliance in adults. It is available in starter and maintenance kits in 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg strengths.

**Manufacturer:** Distributed by: Otsuka America Pharmaceutical, Inc., Rockville, MD 20850.

**Indications:** Abilify Mycite is indicated for the: treatment of adults with schizophrenia and adjunctive treatment of adults with Major Depressive Disorder. Also indicated for the treatment of bipolar I disorder: 1) acute treatment of adults with manic and mixed episodes as monotherapy and as adjunct to lithium or valproate; and 2) maintenance treatment of adults as monotherapy and as adjunct to lithium or valproate.

**Costs:** \$1,650 per 30-tablet kit of any strength *Wholesale Acquisition Cost*

**Summary of Findings:** This drug is being considered for inclusion in the state specific Atypical Antipsychotic Reference List as non-reference.

**Status Recommendation:**  Clinical Edit  PA Required  
 Open Access  Reference List

**Type of PA Criteria:**  Appropriate Indications  Non-Reference  
 No PA Required  Reference

Prepared by: April Ash, PharmD  
 Date: May 13, 2021